75+ Presentations from Top Biopharma in 2026
Engineering Recombinant CC49 IgG for Enhanced Solubility, Purity, and Thermal Stability in CHO Expression Systems
Zhihong Lin, PhD, Associate Research Fellow, Biologics Discovery & Design, Abbott Labs
Integrative Biophysical Characterization for Advanced Modalities in Biotherapeutic Discovery
David Boggs, PhD, Senior Scientist, AbbVie
Fit-for-Purpose Automation: Adapting Platforms to Our Science
Nick Mukhitov, Principal Research Scientist, AbbVie
Innovative Protein Conjugation Strategies Supporting Biotherapeutic and Genetic Medicine Drug Discovery
Ornella D. Nelson, PhD, Senior Scientist, Biotherapeutics & Genetic Medicine, AbbVie
Isotopically-Labeled Carriers to Enhance Recovery Yields and Limit of Detection for siRNA Therapeutics
Megha Chandrashekhar, PhD, Senior Scientist, Amgen Inc.
Next-Generation TCEs: Update from Amgen
Andrew Rankin, PhD, Executive Director, Immuno-Oncology, Amgen Inc.
Advances in Peptide-Based Therapeutics: Design, Applications, and Delivery
Annette Bak, PhD, Head, Advanced Drug Delivery, AstraZeneca
From Prediction to Purification: A Scalable HT Strategy for Multispecifics Manufacturing
Alejandro Carpy, PhD, Senior Director, Protein Sciences and Analytics, Biologics Engineering, AstraZeneca R&D
Novel CD8-Guided T Cell Engagers for Cancer Therapy
Saso Cemerski, PhD, Head, Immune Cell Engagers, AstraZeneca
Scaling Developability: Automating High-Throughput Assays for Early Developability Assessment
Andrew Dippel, PhD, Associate Director, Protein Analytics & Developability, AstraZeneca
Bioanalytical Strategy Considerations for T Cell Engagers
Damien Fink, PhD, Director, Oncology Integrated Bioanalysis, AstraZeneca
From Libraries to Leads: Expanding the Biologics Horizon with de novo Peptide Discovery
Thomas Murray, PhD, Director, Biologics Engineering, AstraZeneca
Lessons Learned from Comprehensive Biophysical Profiling of Clinical Stage Single Domain Antibodies
Gilad Kaplan, PhD, Director, Protein Analytics & Developability, Biologics Engineering, AstraZeneca
High-Throughput Intact Mass QC for IgG and Multispecifics with Automated Data Processing
Xinbi Li, PhD, Associate Principal Scientist, Biologics Engineering, AstraZeneca
Conditional by Design: Engineering Synapse-Gated Trispecific T Cell Engagers for Improved Therapeutic Index
Yariv Mazor, PhD, Executive Director, Head of Protein Engineering & Novel Modalities, Biologics Engineering, AstraZeneca R&D
Optimal Design of Masks for Protease-Activated Biologics: What Works, What Doesn't, and Why
Carolina T. Orozco, PhD, Senior Scientist, AstraZeneca
Automating Mid-Scale Antibody Production: Bridging the Gap in Discovery Workflows with Novel Liquid Handling and Filtration Technologies
Ayla Sessions, Associate Director, AstraZeneca
A Bispecific Antibody that Inhibits PAD2 and PAD4 Activity and the Generation of Citrullinated Autoantigens
Gary P. Sims, PhD, Senior Director, Immunology Biosciences, AstraZeneca
Discovery to Development: Computational Approaches for Immunogenicity De-Risking
Priyanka Gupta, PhD, Principal Scientist, Biotherapeutics, Boehringer Ingelheim Pharmaceuticals, Inc.
Characterization Challenges for Novel Antibody Constructs
Laura Kingsley, Principal Scientist, Biotherapeutics, Boehringer Ingelheim
Discovery of Next-Generation T Cell Engagers
Nicolas Sabarth, PhD, Head, Biotherapeutics Discovery, Boehringer Ingelheim
Leveraging Regulatory Elements to Improve Protein Yields
Monir Ejemel, Senior Scientist, Discovery Biotherapeutics, Bristol Myers Squibb Co.
Immune System Modeling of Immunogenicity for a Biotherapeutic Combination
Lora Hamuro, PhD, Senior Director, Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb
Accelerating Biologics Development with Predictive Stability Modeling
Dan (Cassie) Liu, Principal Statistician, Bristol Myers Squibb
Analytical Control Strategies and Characterization Approaches for Co-Formulated Biologics
Joseph Valente, Associate Scientific Director, Bristol-Myers Squibb
Enabling Analytical Excellence: The Impact of Digital Integration in Clinical Method Performance
Yi Han, PhD, Principal Scientist, Data Science, Biologics Development, Bristol-Myers Squibb
Democratizing Data and AI for Biologics Research
Melody Shahsavarian, PhD, Director, Data Strategy & Digital Transformation, Biotherapeutics Discovery Research, Eli Lilly & Company
A Universal Monoallelic Human Leukocyte Antigen Class II Immunopeptidomic Platform for Defining Therapeutic Protein Immunogenicity Potential
Robert Siegel, PhD, Vice President, Laboratory for Experimental Medicine, Eli Lilly and Company
Mass Photometry Method Development for Viral Vector Characterization
Anastasiia Vasiukhina-Martin, PhD, Advisor, BRD Analytical Development, Eli Lilly and Company
Next-Generation Antibody Conjugates: Delivery of Oligonucleotides for Neurological Indications
Kerstin Hofer, PhD, Matrix & Science Lead, F. Hoffmann-La Roche AG
Fifty Years of Monoclonals: From Hybridomas to Next-Generation Antibody Therapeutics
Paul J. Carter, PhD, Genentech Fellow, Antibody Engineering, Genentech
Evaluating the Immunogenicity Risk of Protein Therapeutics by Augmenting T Cell Epitope Prediction with Clinical Factors
Zicheng Hu, PhD, Principal Scientist, Genentech
Gaps and Progress in Crohn’s Disease, Ulcerative Colitis, and IBD
Mary E. Keir, PhD, Distinguished Scientist, Immunology Diagnostic Discovery, Genentech Inc.
Moving beyond Pan-Cytotoxic Payloads for ADCs: Next-Generation ADCs with Novel Targeted Payloads
Gail D. Lewis, Distinguished Scientist, Discovery Oncology, Genentech, Inc.
Engineering Cytokine Agonists for Therapeutic Applications
Shion Lim, PhD, Principal Scientist & Group Leader, Genentech
Bioanalysis of Novel Antibody and Conjugate Formats Using Mass Spectrometry Approaches
Rachel Liuqing Shi, PhD, Principal Scientist, Genentech, Inc.
Improving Clinical Anti-Drug Immunogenicity Prediction with B Cell Epitopes
Will Thrift, PhD, Principal Artificial Intelligence Scientist, Genentech
TherAbDesign: Bridging AI and Biophysics for Antibody Developability Optimization
Amy Wang, PhD, Senior ML Scientist, Prescient Design, Genentech
Establishing GPCR Production Workflows to Support Large- and Small- Molecule Discovery Programs
Felix Findeisen, PhD, Principal Scientist II, Protein Therapeutics, Gilead Sciences
Biophysical Characterization of New Modalities
Daniela M. Tomazela, PhD, Senior Director, Protein Therapeutics, Gilead Sciences Inc.
Novel Tolerogenic Biologics for Chronic Inflammatory Diseases
Tangsheng Yi, Senior Director, Inflammation Biology and Immunology Discovery, Gilead Sciences
Introducing DRACO, an End-to-End Automated Cell Culture Seed Production Platform
Daniel Poole, PhD, Senior Scientist, Biologics HTP Expression Sciences, Johnson & Johnson Innovative Medicine
Integrating Machine Learning and in silico Property Prediction into a Computational Workflow to Support CMC Development
Colin Stackhouse, Senior Scientist, Biologics Analytical Development, Johnson & Johnson Innovative Medicine
Leveraging Targeted Lentiviral Vectors for in vivo CAR-Cell Generation
James I. Andorko, PhD, Director, In Vivo Discovery, Kite Pharma (formerly Interius BioTherapeutics Inc.)
The Anatomy of Difficulty: What Makes a Protein Challenging to Produce and Characterize, and What Tools Enable Success?
Ethan Dunn, Associate Principal Scientist, Discovery Biologics, Merck
FOXP3 Engineered CD4 T Cells for Use in Treg-Based Immunotherapy
Stella Khiew, PhD, Senior Scientist, Merck & Co.
Harnessing Design of Experiments and Automation, Significantly Improves Transient Protein Production and Accelerates Drug Discovery
Mandy Li, Scientist II, Discovery Biologics, Merck & Co.
From Automation to Visualization: Robotic Sample Preparation, High-Throughput Developability Analysis, and Dashboards
Jan Paulo Zaragoza, PhD, Associate Principal Scientist, Discovery Biologics, Merck
Automating MS Analytical Workflows for Novel Biologics
David Bush, PhD, Principal Scientist, Novartis Institutes for BioMedical Research
IGMotifFinder: Improving Preclinical in silico Immunogenicity Assessment via Integration of Pathogen Similarity Analysis
Michael Gutknecht, PhD, Principal Scientist II, Novartis
Optimizing an Immunoprecipitation Mass Spectrometry Workflow for Enrichment of Surface Proteins: Applications to Surrogate CAR T Cells
Nicolle Serrano SantoDomingo, Senior Scientist, Novartis
Digitalization and Automation of Immunoassay in Bioanalysis
Andreas Hald, PhD, Manager, Research Bioanalysis, Novo Nordisk
Predicting sdAb Biophysical and Developability Properties
Andrei Kamenski, PhD, Senior Data Scientist, Antibody Design, Novo Nordisk AS
Challenges in Digital Representation and Bioanalytical Characterization of Antibody-Drug Conjugates
Joel Bard, PhD, Research Fellow, Bioinformatics, BioMedicine Design, Pfizer
Trispecific Antibodies for Atopic Dermatitis and Other Disorders
Laird Bloom, Senior Director, BioMedicine Design, Pfizer Inc.
GPCR Production Supporting DNA Encoded Library Screening
Timothy K. Craig, PhD, Associate Research Fellow, Pfizer Inc.
From HLA Class II Peptide Presentation to Immunogenicity Screening of Therapeutic Antibodies with HLAIIPred
Mojtaba Haghighatlari, PhD, Senior Principal Machine Learning Scientist, Pfizer Inc.
Control Strategies Tailored for Multispecifics
Wenqin Ni, PhD, Senior Principal Scientist, Analytical Research and Development, Pfizer
Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumor Activity of CD3-Engaging Bispecific Antibodies
David J. DiLillo, PhD, Senior Director, Regeneron Pharmaceuticals
PROPERMAB: An Integrative Framework for in silico Prediction of Antibody Developability Using Machine Learning
Bian Li, PhD, Principal Scientist, Therapeutic Proteins, Regeneron
Antibody-Based AAV Retargeting for Enhanced Skeletal Muscle Transduction
Tri Nguyen, PhD, Principal Scientist, Alternative Format and Antibody Engineering, Regeneron
Engineering Success: High-Throughput Developability for Next-Generation Biotherapeutics
Maniraj Bhagawati, PhD, Senior Scientist and Lab Head, Functional Characterization, Large Molecule Research, Roche pRED
Single-Chain Fab-Based Prodrug Approaches for Chain-Exchange Conditional Activation of T Cell Engager Functionality
Ulrich Brinkmann, PhD, Expert Scientist, Pharma Research & Early Development, Roche Innovation Center, Munich
Formulation Solutions for a Novel Antibody-Oligonucleotide Conjugate
Sima Rahimian, PhD, Senior Scientist, Pharmaceutical Development, Roche
Towards Multispecifics by Design: Large-Scale Data Generation Enabling AI-Based Multispecific Design
Norbert Furtmann, PhD, Head, Biologics AI & Design, Large Molecules Research, Sanofi
Using High-Throughput Analytics to Streamline Multispecific Antibody Production
Brian E. Hall, PhD, Distinguished Scientist, Large Molecule Research, Sanofi
Developability and Manufacturability Challenges for Alternative Modalities
Sagar V. Kathuria, PhD, Senior Principal Scientist, Large Molecule Research, Sanofi
Structural Determination of Small Proteins by CryoEM Using a Coiled Coil Module Strategy
Camille Samson, PhD, Senior Scientist, Structural Biology and Biophysics, Sanofi
The Development of a Lipid Nanoparticle Platform for in vivo CAR T
Andrew J. Sawyer, PhD, Distinguished Scientist & Oncology Project Lead, Immune Cell Reprogramming, Sanofi Group
Anti-Von Willebrand Factor NANOBODY Compound Cablivi Story from Conception to Commercialization
Beneditke Serruys, PhD, Global Head Biologics Innovation, Large Molecule Research Platform, Sanofi
From Proof-of-Concept to Proof-of-Productivity and Scale
Hans M. Bitter, PhD, Head Computational Science, Data Strategy, Takeda Pharmaceutical Co. Ltd.
From Targets to Biologics: AI Powering the Next Leap in Discovery at Takeda
Yves Fomekong Nanfack, PhD, Head of AI/ML Research, Takeda
Peak Exclusion–Driven Deep-Field LC-MS/MS for Enhanced HCP Detection
Leo Wang, PhD, Senior Scientist, Takeda
Mapping the Anti-Drug Antibody Binding Site on Multidomain Biotherapeutics
Xiaobin Zhang, PhD, Associate Director, Takeda Pharmaceuticals
* List updated on February 3. See individual agenda pages for most current list of speakers.